Evidence map›Paper›PMID 33459974›Full record

ReviewPituitary2021

Extending lifespan by modulating the growth hormone/insulin-like growth factor-1 axis: coming of age.

Silvana Duran-Ortiz, Edward O List, Reetobrata Basu, John J Kopchick

Open access · greenAbstract readReview
In one paragraph

Review in Pituitary, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Small-molecule IGF1R inhibitors extend healthspan in a mouse model.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Musculoskeletal Effects of Altered GH Action.Frontiers in physiology · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Alternative Animal Models of Aging Research.Frontiers in molecular biosciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Silvana Duran-OrtizEdison Biotechnology Institute, Ohio University, Athens, USA.ORCID http://orcid.org/0000-0001-8870-4077
Edward O ListEdison Biotechnology Institute, Ohio University, Athens, USA.ORCID http://orcid.org/0000-0002-8230-6331
Reetobrata BasuEdison Biotechnology Institute, Ohio University, Athens, USA.ORCID http://orcid.org/0000-0001-8415-1356
John J KopchickEdison Biotechnology Institute, Ohio University, Athens, USA. Kopchick@ohio.edu.ORCID http://orcid.org/0000-0003-4561-2177
Biotechnology Institute · USFlorida State University · USOhio University · US

Funding

Modulating Growth Hormone Action as a Target for Improved Health and LongevityR01AG059779 · NIA · OHIO UNIVERSITY ATHENS · PI John Joseph Kopchick · 2018 to 2026
$4.7M
NIA NIH HHS AG059779NIA NIH HHS R01 AG059779
6 · The paper itself

Abstract

Progress made in the years of aging research have allowed the opportunity to explore potential interventions to slow aging and extend healthy lifespan. Studies performed in yeast, worms, flies and mice subjected to genetic and pharmacological interventions have given insight into the cellular and molecular mechanisms associated with longevity. Furthermore, it is now possible to effectively modulate pathways that slow aging at different stages of life (early life or at an adult age). Interestingly, interventions that extend longevity in adult mice have had sex-specific success, suggesting a potential link between particular pathways that modulate aging and sex. For example, reduction of the growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis at an adult age extends lifespan preferentially in females. Moreover, several postnatal dietary interventions tested by the 'Intervention Testing Program (ITP)' from the National Institute of Aging (NIA) have shown that while pharmacological interventions like rapamycin affect the IGF-1/insulin pathway and preferentially extend lifespan in females; dietary compounds that target other cellular pathways are effective only in male mice-indicating mutually exclusive sex-specific pathways. Therefore, a combination of interventions that target non-overlapping aging-related pathways appears to be an effective approach to further extend healthy lifespan in both sexes. Here, we review the germline and postnatal mouse lines that target the GH/IGF-1 axis as a mechanism to extend longevity as well as the dietary compounds that tested positive in the NIA program to increase lifespan. We believe that the interventions reviewed in this paper could constitute feasible combinations for an extended healthy lifespan in both male and female mice.

Indexed as

Human Growth HormoneLongevityAgingAnimalsFemaleGrowth HormoneInsulin-Like Growth Factor IMaleMiceGrowth HormoneHuman Growth HormoneInsulin-Like Growth Factor IAgingGHRKO miceGrowth hormoneIGF-IIntervention testing programLongevity

Identifiers

PMID33459974
PMCPMC8122064
OpenAlexW3121447888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.